Portfolio companies news

11 January 2016

Epic Sciences Receives CAP Accreditation

Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory. The CAP Laboratory Accreditation Program is recognized bythe United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.

08 January 2016

Clearside Biomedical, Inc. Files Registration Statement for Proposed Initial Public Offering

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission related to Clearside’s proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not been determined. 

08 January 2016

Sherer and White to Receive 2016 Georgia Bio Industry Growth Awards

Todd Sherer, PhD, Associate Vice President & Executive Director of the Emory University Office of Technology Transfer, and Daniel White, President and CEO of Clearside Biomedical Inc. are the recipients of the 2016 Georgia Bio Industry Growth Awards.

08 January 2016

Atlas Genetics appoints Bob Johnston as Chief Financial Officer

Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces the appointment of Bob Johnston as Chief Financial Officer, who will be based in the recently opened Boston office.

07 January 2016

Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis

Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, announced that the U.S. Food and Drug Administration (FDA) and Health Canada have accepted the company's Investigational New Drug (IND) application and Clinical Trial Application (CTA), respectively, for cenicriviroc (CVC) for the treatment of primary sclerosing cholangitis (PSC).

05 January 2016

Clearside Biomedical, Inc. Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced positive results from the company’s Phase 2 clinical trial of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using suprachoroidal space (SCS™) drug administration for the treatment of macular edema associated with non-infectious uveitis.

04 January 2016

Circulating Tumor Cells Linked with Treatment Resistance and Response in Prostate Cancer Patients

Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies. Furthermore, high diversity among CTCs was not associated with resistance to taxane-based chemotherapy.  This suggests that patients likely to fail anti-androgen therapies but potentially benefit from chemotherapy can be identified.

04 January 2016

Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer

Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s entinostat, an investigational oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells and regulatory T-cells), in patients with heavily pre-treated, recurrent ovarian cancer. 

16 December 2015

Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced that it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures. Sites participating in this global study have completed screening patients. After establishing eight weeks of baseline seizure frequency, patients randomized in the study undergo a two-week titration period followed by a twelve-week maintenance period. 

16 December 2015

Clinical Data from ReVision Optics’ Raindrop Near Vision Inlay Featured in Two Presentations at the OIS@AAO Conference

ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data from its Raindrop® Near Vision Inlay for the treatment of presbyopia was the subject of two presentations at the 2015 OIS@AAO conference, held last month in Las Vegas.